A detailed history of Valeo Financial Advisors, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Valeo Financial Advisors, LLC holds 10,223 shares of TGTX stock, worth $351,671. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,223
Holding current value
$351,671
% of portfolio
0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$17.21 - $25.28 $175,937 - $258,437
10,223 New
10,223 $239,000
Q1 2024

Apr 19, 2024

SELL
$13.02 - $21.3 $259,827 - $425,062
-19,956 Reduced 31.53%
43,344 $659,000
Q4 2023

Jan 29, 2024

BUY
$6.68 - $18.81 $10,020 - $28,214
1,500 Added 2.43%
63,300 $1.08 Million
Q3 2023

Oct 19, 2023

BUY
$8.36 - $26.5 $12,540 - $39,750
1,500 Added 2.49%
61,800 $516,000
Q2 2023

Jul 14, 2023

SELL
$15.48 - $35.0 $77,400 - $175,000
-5,000 Reduced 7.66%
60,300 $1.5 Million
Q1 2023

Apr 17, 2023

SELL
$10.23 - $19.34 $35,805 - $67,690
-3,500 Reduced 5.09%
65,300 $982,000
Q4 2022

Feb 09, 2023

BUY
$5.01 - $11.83 $179,859 - $424,697
35,900 Added 109.12%
68,800 $813,000
Q3 2022

Oct 31, 2022

SELL
$4.57 - $8.4 $41,587 - $76,440
-9,100 Reduced 21.67%
32,900 $195,000
Q2 2022

Aug 03, 2022

BUY
$3.74 - $10.66 $93,126 - $265,434
24,900 Added 145.61%
42,000 $178,000
Q1 2022

Apr 28, 2022

SELL
$7.81 - $20.45 $42,955 - $112,475
-5,500 Reduced 24.34%
17,100 $163,000
Q4 2021

Jan 07, 2022

BUY
$15.2 - $35.51 $97,280 - $227,264
6,400 Added 39.51%
22,600 $429,000
Q3 2021

Nov 02, 2021

BUY
$21.78 - $40.45 $352,836 - $655,290
16,200 New
16,200 $539,000
Q2 2021

Jul 22, 2021

SELL
$32.5 - $48.96 $32,500 - $48,960
-1,000 Closed
0 $0
Q1 2021

Apr 12, 2021

BUY
$41.61 - $54.3 $20,805 - $27,150
500 Added 100.0%
1,000 $48,000
Q3 2020

Oct 28, 2020

BUY
$18.49 - $27.24 $9,245 - $13,620
500 New
500 $13,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Valeo Financial Advisors, LLC Portfolio

Follow Valeo Financial Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Valeo Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Valeo Financial Advisors, LLC with notifications on news.